Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT04277702
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT04277702 -
2020-000715-71
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT04277702. Randomized; quadruple masking; primary purpose treatment. Start 2020-05 (anticipated); primary completion 2023-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease
- Acronym
- CADET-PAD
- Condition
- Peripheral Arterial Disease
- Condition
- Peripheral Vascular Diseases
- Condition
- Lower Limb Ischemia
- Condition
- Atherosclerosis of Artery
- Intervention (Drug)
- Montelukast 10mg
- Intervention (Procedure)
- Endovascular treatment
- Intervention (Drug)
- Standard anti-platelet treatment
- Lead sponsor
- Jagiellonian University
Record details
- Record id
cardio:ct-nct04277702- Content hash
e327cb7e72b061c3ed9bdaef3c5cbca5a26ef396a1586805ff49b7def6629931